Fractyl Health, Inc. Common Stock (GUTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has a cash flow conversion efficiency ratio of -2.256x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.34 Million) by net assets ($9.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GUTS equity financing ratio to measure how much of total assets are equity-financed.
Fractyl Health, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Fractyl Health, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Fractyl Health, Inc. Common Stock (GUTS) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Fractyl Health, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanmiglobal
KO:053690
|
-0.005x |
|
Shin Heung Energy & Electronics Co.Ltd
KQ:243840
|
0.043x |
|
Caravel Minerals Ltd
AU:CVV
|
-0.375x |
|
Riber S.A
PA:ALRIB
|
-0.100x |
|
GR Silver Mining Ltd
V:GRSL
|
-0.097x |
|
Fairchem Organics Limited
NSE:FAIRCHEMOR
|
0.117x |
|
ADDvise Group B
ST:ADDV-B
|
0.032x |
|
Suria Capital Holdings Bhd
KLSE:6521
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Fractyl Health, Inc. Common Stock from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see GUTS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $9.46 Million | $-90.33 Million | -9.550x | -314.31% |
| 2024-09-30 | $28.42 Million | $-65.52 Million | -2.305x | -1849.78% |
| 2023-09-30 | $-325.06 Million | $-42.82 Million | 0.132x | -28.12% |
| 2022-09-30 | $-252.32 Million | $-46.24 Million | 0.183x | +14.65% |
| 2021-09-30 | $-209.32 Million | $-33.46 Million | 0.160x | +107.69% |
| 2020-09-30 | $14.95 Million | $-31.07 Million | -2.078x | -1179.23% |
| 2019-09-30 | $-144.00 Million | $-27.73 Million | 0.193x | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more